Read more
17:24 · 6 April 2026

Wall Street rebound continues ahead of the US open 📈Netflix surges on Goldman Sachs upgrade

-
-
Open account Download free app
-
-
Open account Download free app
Ahead of the Wall Street open, US index futures gave back a small portion of their earlier gains. Nasdaq 100 futures pulled back from around 24,380 to 24,300 points, but are still up more than 0.7% on an intraday basis. Investor focus is on the US ISM Services data due at 3 PM GMT, as well as ongoing negotiations between US mediators and their Iranian counterparts, reportedly conducted via Pakistan. Iran has initially refused to reopen the Strait of Hormuz in exchange for a ceasefire, but talks remain ongoing. Donald Trump has set Wednesday, April 8 (1 AM GMT), as a key deadline for the next phase of the conflict - either escalation, including potential strikes on infrastructure, or de-escalation.

Raymond James notes that despite the outbreak of war with Iran, equity markets have remained surprisingly resilient, with no significant sell-off. According to the bank, strong macroeconomic data from early 2026 and the structure of the oil market—where elevated prices are concentrated in the short term - have helped stabilize both credit and equity markets.

US100 (D1 timeframe)

This has limited downside pressure so far, but the next key test for investors will be the deadline set by Donald Trump for reaching a deal with Iran. From a technical perspective, Nasdaq 100 futures remain within a downward price channel and are still trading below the 200-session moving average, which lies დაახლოებით 200 points higher.

Source: xStation5

Ed Yardeni on the US equity market

Ed Yardeni, founder of Yardeni Research, remains constructive on the S&P 500, arguing that current valuations are relatively attractive and that equities have historically performed well following major US military conflicts.

  • The S&P 500 was higher two years after each of the last four major conflicts—World War II, the Korean War, the Gulf War, and the Iraq War—with gains ranging from 31% to 44%.
  • Yardeni argues that current market levels offer relatively attractive entry points. The forward P/E ratio peaked at 23 last October and has since declined by around 15%.
  • At the same time, forward earnings have risen by 12.7%, reaching record highs, suggesting that the decline in valuations reflects multiple compression rather than weaker fundamentals.
  • Initially, the compression was driven by concerns over AI-related profitability, and later by fears that the conflict could trigger a global recession.
  • Despite this, analysts have not materially revised down earnings expectations and continue to raise forecasts.
  • According to FactSet data, the forward 12-month P/E has fallen to 19.8—below the five-year average of 19.9 and slightly above the 10-year average of 18.9.

Source: xStation5

Corporate news

  • Netflix (NFLX.US) – shares are up nearly 2% pre-market after Goldman Sachs upgraded the stock from “neutral” to “buy,” citing continued leadership in content acquisition and development, as well as strong potential for capital returns to shareholders.
  • Soleno Therapeutics – shares surged लगभग 40% after Neurocrine Biosciences announced an agreement to acquire the company for $53 per share in cash, valuing the deal at around $2.9 billion. The acquisition is expected to expand Neurocrine’s drug portfolio and strengthen its position in endocrinology and rare diseases.
  • Twilio – shares gained more than 3% following an upgrade by Jefferies from “hold” to “buy,” with the bank highlighting Twilio’s key role in the development of voice-based artificial intelligence solutions.

Source: xStation5

6 April 2026, 18:11

BREAKING: US100 loses after lower than expected and inflationary US ISM services data 📉

6 April 2026, 15:56

NATGAS under pressure amid increasing risk of super El-Nino in 2026 📉

6 April 2026, 13:37

Bitcoin gains 3.5% approaching $70k level 📈

6 April 2026, 13:18

📈 US100 surges 1%

The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.

The financial instruments we offer, especially CFDs, can be highly risky. Please consider if you understand the risks and can afford the loss of capital. XTB is regulated by the CMA

The financial instruments we offer, especially CFDs, can be highly risky. Please consider if you understand the risks and can afford the loss of capital. XTB is regulated by the CMA

The financial instruments we offer are risky. XTB is regulated by the CMA.